Colle J P, Ohayon J, Besse P
Arch Mal Coeur Vaiss. 1985 Nov;78(12):1843-51.
Nineteen patients with left ventricular hypertrophy were given intravenous calcium antagonists: 9 patients received intravenous verapamil (VPM IV) and 10 patients diltiazem (DTZ) by intracoronary and then intravenous injection. Systemic and pulmonary resistances, cardiac output, left ventricular and aortic pressures, isometric contractility, isometric relaxation and left ventricular compliance were studied in sinus rhythm, during atrial and then ventricular pacing at 120/min and finally after tachycardia before and after administration of calcium antagonists. Left ventriculography in the 30 degrees RAO projection in sinus rhythm was performed before and after injection of the calcium antagonists to study the variations in the end diastolic volume, mass and mass-volume ratio. Finally, frame by frame numerisation of the ventriculographies during systole and diastole helped evaluate variations in amplitude, time and velocity of fibre shortening or lengthening. The administration of the calcium antagonists did not have any significant effect on heart rate (-2.8 +/- 10 p. 100, NS) or indices of isometric contractility (delta Vmax + 4 +/- 43 p. 100, NS). Significant falls in systemic and pulmonary resistances (-15 +/- 23 p. 100, p less than 0.05 and - 26 +/- 32 p. 100, p less than 0.05, respectively) and an increase in systolic index (+ 15.5 p. 100 +/- 12 p. 100, p less than 0.01) were observed. The improvement in left ventricular ejection was independent of the variation in resistances but was closely related to variations of parameters of relaxation. The effects on volumic compliance and filling velocities were also closely related to variations in relaxation (p less than 0.05 and p less than 0.01). Calcium antagonists protected left ventricular ejection during supraventricular tachycardia and prevented the changes in left ventricular relaxation observed during arrhythmias and after tachycardia.(ABSTRACT TRUNCATED AT 250 WORDS)
19例左心室肥厚患者接受静脉注射钙拮抗剂治疗:9例患者接受静脉注射维拉帕米(VPM IV),10例患者通过冠状动脉内注射后再静脉注射地尔硫䓬(DTZ)。研究了窦性心律、心房起搏(频率为120次/分钟)、心室起搏(频率为120次/分钟)以及心动过速前后在给予钙拮抗剂前后的全身和肺血管阻力、心输出量、左心室和主动脉压力、等长收缩力、等长舒张和左心室顺应性。在窦性心律下,于注射钙拮抗剂前后进行30度右前斜位的左心室造影,以研究舒张末期容积、质量和质量-容积比的变化。最后,对心室造影在收缩期和舒张期逐帧计数,有助于评估纤维缩短或延长的幅度、时间和速度的变化。钙拮抗剂的给药对心率(-2.8±10%,无显著性差异)或等长收缩力指标(△Vmax +4±43%,无显著性差异)无任何显著影响。观察到全身和肺血管阻力显著下降(分别为-15±23%,p<0.05和-26±32%,p<0.05)以及收缩指数增加(+15.5%±12%,p<0.01)。左心室射血的改善与阻力变化无关,但与舒张参数的变化密切相关。对容积顺应性和充盈速度的影响也与舒张变化密切相关(p<0.05和p<0.01)。钙拮抗剂在室上性心动过速期间保护左心室射血,并防止心律失常期间及心动过速后观察到的左心室舒张变化。(摘要截选至250字)